Identifiant pérenne de la notice : 212500821
Notice de type
Notice de regroupement
Note publique d'information : Growth factor receptors have long been known to drive malignant transformation and
cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system
is likely the best described membrane receptor tyrosine kinase family in malignant
tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab
(Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer,
a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive
cancers invariably develop resistance to the antibody after some time. Recent clinical
studies have revealed that these refractory tumors are still responsive to inhibition
of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb).
Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER
tyrosine kinase inhibitors are in the pipeline of many drug developing companies and
are being evaluated in the clinical setting
paprika.idref.fr
data.idref.fr
Documentation
